Cardiovascular Biomarkers Pathophysiology and Disease Management /

• Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
• Άλλοι συγγραφείς: Morrow, David A. (Επιμελητής έκδοσης)
• Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Totowa, NJ : Humana Press, 2006.
• Σειρά: Contemporary Cardiology
• Θέματα: Medicine.; Cardiology.; Medicine & Public Health.

 So rapidly has the number of cardiac assays available grown, and then improved, that current biomarkers not only diagnose cardiovascular disease, but also frame treatment strategies. In Cardiovascular Biomarkers: Pathophysiology and Disease Management, a distinguished panel of internationally recognized opinion makers and experts in clinical and laboratory medicine synthesize the latest developments in the use of cardiac biomarkers by the practicing physician. The authors focus on integrating biomarkers into the contemporary clinical management of patients with cardiovascular disease, emphasizing clinical studies, evidence-based diagnostic algorithms, and critical pathways for triage and therapy, whenever available. They also illuminate the connections between specific biomarkers and the basic pathophysiology of cardiovascular disease, explain the analytical properties of the assays relevant to clinical practice, and highlight emerging biomarkers and novel directions for biomarker development. Numerous figures, illustrations, and tables make key evidence and practical guidelines easily accessible. State-of-the-art and highly practical, Cardiovascular Biomarkers: Pathophysiology and Disease Management makes clear to today's busy cardiologists, emergency room physicians, and internists how the various assays perform, which ones they should order when evaluating their patients, and how the results of a biomarker assay can guide their therapeutic approaches. 

 Biomarkers of Necrosis -- Biomarkers of Myocardial Necrosis -- Analytical Issues for Clinical Use of Cardiac Troponin -- Defining Myocardial Infarction -- Biomarkers in the Emergency Department -- Cardiac Troponin for Risk Assessment and Management of Non-ST-Elevation Acute Coronary Syndrome -- Biomarkers of Necrosis for Risk Assessment and Management of ST-Elevation Myocardial Infarction -- Cardiac Troponin After Revascularization Procedures -- Biomarkers of Necrosis in Heart Failure -- Is There a Role for Cardiac Troponin and Other Biomarkers in Patients With Pulmonary Embolism? -- Cardiac Troponin in Conditions Other Than Acute Coronary Syndromes -- Degradation of Cardiac Troponins -- Biomarkers of Ischemia -- Developing a Marker of Ischemia -- Emerging Biomarkers of Myocardial Ischemia -- Biomarkers of Inflammation -- Inflammation in Cardiovascular Disease -- Analytic Issues for Clinical Use of C-Reactive Protein -- C-Reactive Protein as a Tool for Risk Assessment in Primary Prevention -- High-Sensitivity C-Reactive Protein for Risk Assessment in Acute Coronary Syndromes -- Beyond C-Reactive Protein -- Biomarkers of Inflammation -- Biomarkers of Infection and Risk of Coronary Heart Disease -- Biomarkers of Hemodynamic Stress -- Biology of Natriuretic Peptides -- Analytic Issues for Clinical Use of B-Type Natriuretic Peptide and N-Terminal Pro B-Type Natriuretic Peptide -- Clinical Use of Natriuretic Peptides for the Diagnosis and Management of Heart Failure -- Natriuretic Peptides in Acute and Chronic Coronary Artery Disease -- Novel Markers of Hemodynamic Stress -- Biomarkers of Platelet Function and Hemostasis -- Clinical and Research Applications of Markers of Thrombosis -- Measures of Platelet Activation and Aggregation -- Monocyte-Platelet Aggregates in Patients With Ischemic Heart Disease -- Biomarkers of Dyslipidemia and Lipid Modification -- Measurement of Atherogenic Lipoproteins in Cardiovascular Risk Assessment -- Lipoprotein-Associated Phospholipase A2 and Other Lipid-Related Biomarkers in Cardiovascular Disease -- Contemporary and Future Applications of Biomarkers in clinical care -- A Multimarker Approach to Evaluation of Patients With Acute Coronary Syndrome -- Cardiac Biomarkers by Point-of-Care Testing -- Proteomics and Discovery of Cardiovascular Biomarkers -- Genetic Markers in Cardiovascular Disease.